1
|
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins.
|
J Clin Invest
|
2003
|
1.71
|
2
|
Cell surface-binding motifs of L2 that facilitate papillomavirus infection.
|
J Virol
|
2003
|
1.68
|
3
|
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
|
J Virol
|
2004
|
1.66
|
4
|
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.
|
Nat Med
|
2005
|
1.61
|
5
|
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe.
|
Vaccine
|
2003
|
1.56
|
6
|
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.
|
Expert Rev Vaccines
|
2007
|
1.50
|
7
|
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.
|
Cancer Res
|
2007
|
1.43
|
8
|
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.
|
Cancer Res
|
2007
|
1.39
|
9
|
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
|
Vaccine
|
2009
|
1.38
|
10
|
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency.
|
Cancer Res
|
2005
|
1.32
|
11
|
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus.
|
J Virol
|
2004
|
1.30
|
12
|
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
|
Clin Cancer Res
|
2008
|
1.29
|
13
|
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.
|
Cancer Res
|
2013
|
1.27
|
14
|
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6.
|
Cancer Res
|
2004
|
1.24
|
15
|
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging.
|
Hum Gene Ther
|
2007
|
1.23
|
16
|
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis.
|
BMC Gastroenterol
|
2006
|
1.23
|
17
|
Activation of Akt as a mechanism for tumor immune evasion.
|
Mol Ther
|
2008
|
1.22
|
18
|
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
|
J Immunol
|
2003
|
1.21
|
19
|
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.
|
J Immunother
|
2005
|
1.19
|
20
|
Immunotherapy for cervical cancer: Research status and clinical potential.
|
BioDrugs
|
2010
|
1.18
|
21
|
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
|
Hum Gene Ther
|
2002
|
1.17
|
22
|
Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
|
Vaccine
|
2007
|
1.12
|
23
|
Therapeutic HPV DNA vaccines.
|
Immunol Res
|
2010
|
1.12
|
24
|
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity.
|
Cell Biosci
|
2011
|
1.11
|
25
|
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.
|
Cancer Immunol Immunother
|
2012
|
1.10
|
26
|
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency.
|
Vaccine
|
2007
|
1.07
|
27
|
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
|
J Mol Med (Berl)
|
2008
|
1.04
|
28
|
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
|
Cancer Immunol Immunother
|
2008
|
1.04
|
29
|
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
|
Vaccine
|
2004
|
1.03
|
30
|
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
|
Infect Immun
|
2008
|
1.02
|
31
|
Inactivation of viruses by coherent excitations with a low power visible femtosecond laser.
|
Virol J
|
2007
|
1.02
|
32
|
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.
|
Mol Ther
|
2010
|
1.01
|
33
|
Endoscopic retrograde cholangiography in the diagnosis and treatment of mucobilia.
|
Scand J Gastroenterol
|
2008
|
1.01
|
34
|
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions.
|
Clin Cancer Res
|
2007
|
1.01
|
35
|
Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life.
|
Hum Gene Ther
|
2005
|
1.01
|
36
|
DNA vaccines for cancer.
|
IDrugs
|
2003
|
1.00
|
37
|
A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
|
J Biomed Sci
|
2006
|
1.00
|
38
|
Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity.
|
Cancer Res
|
2010
|
0.99
|
39
|
Perspectives for preventive and therapeutic HPV vaccines.
|
J Formos Med Assoc
|
2010
|
0.99
|
40
|
Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser.
|
J Biomed Opt
|
2010
|
0.99
|
41
|
Dose-dense chemotherapy improves mechanisms of antitumor immune response.
|
Cancer Res
|
2012
|
0.99
|
42
|
HPV DNA vaccines.
|
Front Biosci
|
2003
|
0.98
|
43
|
Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process.
|
J Biomed Opt
|
2007
|
0.98
|
44
|
In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination.
|
Cell Biosci
|
2011
|
0.97
|
45
|
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
|
Mol Ther
|
2009
|
0.97
|
46
|
Emerging human papillomavirus vaccines.
|
Expert Opin Emerg Drugs
|
2012
|
0.96
|
47
|
Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
|
Hum Gene Ther
|
2011
|
0.96
|
48
|
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth.
|
Adv Healthc Mater
|
2013
|
0.95
|
49
|
Development of a DNA vaccine targeting Merkel cell polyomavirus.
|
Vaccine
|
2011
|
0.95
|
50
|
Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
|
J Biomed Sci
|
2005
|
0.95
|
51
|
Intrahepatic sarcomatoid cholangiocarcinoma: clinical analysis of seven cases during a 15-year period.
|
Chang Gung Med J
|
2009
|
0.95
|
52
|
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.
|
Eur J Immunol
|
2009
|
0.94
|
53
|
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells.
|
Vaccine
|
2008
|
0.94
|
54
|
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
|
Cancer Immunol Immunother
|
2013
|
0.94
|
55
|
Immune mechanism of the antitumor effects generated by bortezomib.
|
J Immunol
|
2012
|
0.93
|
56
|
Generation and characterization of an ascitogenic mesothelin-expressing tumor model.
|
Cancer
|
2007
|
0.93
|
57
|
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.
|
Clin Cancer Res
|
2013
|
0.92
|
58
|
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.
|
Biologics
|
2008
|
0.92
|
59
|
Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer.
|
Hum Gene Ther
|
2009
|
0.91
|
60
|
Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.
|
PLoS One
|
2012
|
0.91
|
61
|
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.
|
Vaccine
|
2008
|
0.90
|
62
|
Therapeutic HPV DNA vaccines.
|
Expert Rev Vaccines
|
2009
|
0.90
|
63
|
Control of HPV infection and related cancer through vaccination.
|
Recent Results Cancer Res
|
2014
|
0.89
|
64
|
Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
|
Hum Gene Ther
|
2004
|
0.89
|
65
|
Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
|
J Biomed Sci
|
2010
|
0.89
|
66
|
Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles.
|
Mol Ther
|
2003
|
0.89
|
67
|
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
|
Int J Cancer
|
2013
|
0.88
|
68
|
Combination of viral oncolysis and tumor-specific immunity to control established tumors.
|
Clin Cancer Res
|
2009
|
0.88
|
69
|
DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
|
Vaccine
|
2010
|
0.88
|
70
|
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects.
|
J Biomed Sci
|
2009
|
0.88
|
71
|
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.
|
Hum Gene Ther
|
2007
|
0.87
|
72
|
DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.
|
Immunol Lett
|
2007
|
0.87
|
73
|
Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
|
Int J Cancer
|
2007
|
0.87
|
74
|
DNA vaccine for cancer immunotherapy.
|
Hum Vaccin Immunother
|
2014
|
0.87
|
75
|
Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
|
Cancer Res
|
2007
|
0.87
|
76
|
DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
|
Hum Gene Ther
|
2005
|
0.86
|
77
|
Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen.
|
Cell Biosci
|
2012
|
0.86
|
78
|
Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency.
|
Vaccine
|
2009
|
0.86
|
79
|
RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.
|
Hum Gene Ther
|
2008
|
0.86
|
80
|
Critical illness-related corticosteroid insufficiency in patients with severe acute biliary pancreatitis: a prospective cohort study.
|
Crit Care
|
2009
|
0.86
|
81
|
Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
|
Vaccine
|
2004
|
0.85
|
82
|
Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
|
J Immunol
|
2008
|
0.85
|
83
|
Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
|
Immunol Lett
|
2006
|
0.85
|
84
|
Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing.
|
Mol Ther
|
2012
|
0.85
|
85
|
Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation.
|
J Biomed Sci
|
2010
|
0.85
|
86
|
Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
|
J Biomed Sci
|
2011
|
0.84
|
87
|
A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response.
|
J Biomed Sci
|
2004
|
0.84
|
88
|
Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects.
|
J Biomed Sci
|
2002
|
0.84
|
89
|
Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors.
|
J Biomed Sci
|
2010
|
0.83
|
90
|
HPV pseudovirions as DNA delivery vehicles.
|
Ther Deliv
|
2011
|
0.83
|
91
|
LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines.
|
Vaccine
|
2011
|
0.83
|
92
|
Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
|
J Immunol
|
2008
|
0.83
|
93
|
Carrageenan as an adjuvant to enhance peptide-based vaccine potency.
|
Vaccine
|
2010
|
0.82
|
94
|
Uterine artery embolization for symptomatic uterine leiomyoma and adenomyosis.
|
J Formos Med Assoc
|
2003
|
0.82
|
95
|
alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
|
Vaccine
|
2008
|
0.82
|
96
|
Immunotherapeutic strategies employing RNA interference technology for the control of cancers.
|
J Biomed Sci
|
2006
|
0.82
|
97
|
Characterization of human papillomavirus type 11-specific immune responses in a preclinical model.
|
Laryngoscope
|
2010
|
0.81
|
98
|
Preventive and therapeutic HPV vaccines.
|
Curr Opin Investig Drugs
|
2007
|
0.81
|
99
|
Regulatory T cells: potential target in anticancer immunotherapy.
|
Taiwan J Obstet Gynecol
|
2007
|
0.81
|
100
|
Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide.
|
Cell Biosci
|
2013
|
0.81
|
101
|
Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
|
PLoS One
|
2013
|
0.80
|
102
|
Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.
|
Vaccine
|
2010
|
0.80
|
103
|
Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model.
|
Immunobiology
|
2012
|
0.80
|
104
|
Aggressive multimodality treatment for intra-hepatic recurrence of hepatocellular carcinoma following hepatic resection.
|
Chang Gung Med J
|
2005
|
0.80
|
105
|
Innovative DNA vaccine to break immune tolerance against tumor self-antigen.
|
Hum Gene Ther
|
2013
|
0.80
|
106
|
Serum levels of apolipoprotein A-I and high-density lipoprotein can predict organ failure in acute pancreatitis.
|
Crit Care
|
2015
|
0.79
|
107
|
Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency.
|
J Virol
|
2009
|
0.79
|
108
|
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.
|
PLoS One
|
2012
|
0.79
|
109
|
Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
|
J Mol Med (Berl)
|
2013
|
0.79
|
110
|
Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors.
|
Cancer Immunol Immunother
|
2011
|
0.79
|
111
|
Poorly expandable common bile duct with stones on endoscopic retrograde cholangiography.
|
World J Gastroenterol
|
2012
|
0.79
|
112
|
Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis.
|
Histopathology
|
2010
|
0.78
|
113
|
Diagnosis and staging of gallbladder carcinoma. Evaluation with dynamic MR imaging.
|
Clin Imaging
|
2002
|
0.78
|
114
|
Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
|
Eur J Immunol
|
2004
|
0.78
|
115
|
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
|
BMC Cancer
|
2011
|
0.78
|
116
|
Femtosecond laser treatment enhances DNA transfection efficiency in vivo.
|
J Biomed Sci
|
2009
|
0.78
|
117
|
Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen.
|
Cell Biosci
|
2013
|
0.78
|
118
|
Safety and efficacy of image-guided percutaneous biopsies in the diagnosis of gastrointestinal stromal tumors.
|
Clin Imaging
|
2012
|
0.78
|
119
|
Sclerosing hepatocellular carcinoma: clinicopathologic features in seven patients from Taiwan and review of the literature.
|
Hepatogastroenterology
|
2005
|
0.78
|
120
|
Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T cells in peritoneal space.
|
J Immunother
|
2012
|
0.77
|
121
|
Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer.
|
PLoS One
|
2013
|
0.77
|
122
|
Radiation dose exposure of patients undergoing 320-row cardiac CT for assessing coronary angiography and global left ventricular function.
|
Int J Cardiovasc Imaging
|
2012
|
0.76
|
123
|
Triphasic dynamic CT findings of 63 hepatic focal nodular hyperplasia in 46 patients: correlation with size and pathological findings.
|
Abdom Imaging
|
2008
|
0.76
|
124
|
Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
|
J Biomed Sci
|
2005
|
0.76
|
125
|
Vaccines against human papillomavirus.
|
Front Biosci
|
2007
|
0.76
|
126
|
Immunological research using RNA interference technology.
|
Immunology
|
2007
|
0.75
|
127
|
Direct peroral cholangioscopy and pancreatoscopy for diagnosis of a pancreatobiliary fistula caused by an intraductal papillary mucinous neoplasm of the pancreas: a case report.
|
Dig Endosc
|
2011
|
0.75
|